miR-365 inhibits cell invasion and migration of triple negative breast cancer through ADAM10.
Triple negative breast cancer (TNBC) refers to breast cancer that lacks progesterone receptor (PR), estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). MicroRNA-365 (miR-365), a new-found microRNA, has been reported to possess significant functions in a multitude of human cancers. The purpose of this study was to detect thoroughly the molecular mechanisms of miR-365 that underlie the progress of TNBC. The mRNA levels of miR-365 and A Disintegrin and Metalloprotease 10 (ADAM10) were measured by real-time polymerase chain reaction (RT-PCR). Luciferase activity report was applied to verify that ADAM10 was a direct target gene of miR-365. Cell proliferation ability was measured by MTT assay. Transwell assay was utilized to test cell migratory and invasive abilities. We found that miR-365 was low-expressed in breast cancer tissues and 5 TNBC cell lines compared with the paracancerous samples and a normal cell line MCF10A. Meanwhile, we discovered that the expression of ADAM10 was higher in the 5 TNBC cell lines than in the normal cell line MCF10A. The proliferation, migration and invasion abilities were suppressed by overexpression of miR-365, whereas they were enhanced by interfering miR-365 in breast cancer. The luciferase reporter assay demonstrated that miR-365 directly targeted ADAM10 through directly binding to the 3'-untranslated region (3'-UTR). And the expression of ADAM10 was reduced by exogenous overexpression of miR-365, while it was increased by transfecting of miR-365 inhibitor in MDA-MB-231 and BT483 cells. Furthermore, re-expression of ADAM10 reversed partial functions of the suppressive roles on cell proliferation, migration and invasion by miR-365 TNBC. MiR-365 inhibited the proliferation, migration and invasion through directly binding to the 3'-UTR of ADAM10 mRNA in TNBC. It is suggested that miR-365/ADAM10 axis may present a new target for the treatment of breast cancer.